1. EP1116 Integrated pathway analysis identifies a 3-gene signature predicting platinum response and outcome of high grade serous ovarian carcinoma patients. (1st November 2019) Authors: Bignotti, E; Benvenuto, G; Paracchini, L; Zanotti, L; Romani, C; Tognon, G; Calura, E; Vicini, D; Adorni, M; Paderno, MC; Paderno, MC; Bianchi, T; Odicino, F; Sartori, E; Ravaggi, A; D'Incalci, M; Marchini, S; Todeschini, P; Romualdi, C Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 4 Page Start: A582 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. EP814 TGFβ pathway activation is a predictor of progression free and overall survival in advanced high-grade serous ovarian cancer according to the surgical aggressiveness and rate of cytoreduction of different oncologic centers. (1st November 2019) Authors: Ceppi, L; Grassi, T; Romualdi, C; Di Lorenzo, P; Palazzi, S; Biagioli, E; Garbi, A; Paracchini, L; Landoni, F; Aletti, GD; Colombo, N; Fruscio, R; Marchini, S; D'Incalci, M Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 4 Page Start: A450 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Intratumor Heterogeneity and Its Impact on Drug Distribution and Sensitivity. Issue 2 (14th May 2014) Authors: Fuso Nerini, I; Morosi, L; Zucchetti, M; Ballerini, A; Giavazzi, R; D'Incalci, M Journal: Clinical pharmacology & therapeutics Issue: Volume 96:Issue 2(2014) Page Start: 224 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Not only tumor but also therapy heterogeneity. (12th October 2017) Authors: Garattini, S; Fuso Nerini, I; D'Incalci, M Journal: Annals of oncology Issue: Volume 29:Number 1(2018) Page Start: 13 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P01.067 Multicenter, single arm, phase II trial on the efficacy of ortataxel in recurrent glioblastoma: the experience of the Italian Association of Neuro-Oncology. (19th September 2018) Authors: Simonetti, G; Silvani, A; Biagioli, E; Botturi, A; Caroli, M; de Simone, I; Fregoni, V; Gaviani, P; Lanza, A; Marchioni, E; Pace, A; Quaquarini, E; Salmaggi, A; D'Incalci, M Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 3 Page Start: iii245 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗